66 completed, 19 terminated, 6 withdrawn, 3 recruiting. 55 Phase 2, 54 Phase 1, 5 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow romidepsin: new trials by email Literature Review of romidepsin trials Research Report on romidepsin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents Romidepsin, Durvalumab - Bladder Cancer | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2025-06-24 | 2026-07-30 |
| Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma CC-486 (5-azacitidine), Duvelisib, Romidepsin - Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2022-11-03 | 2022-11-04 | |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer Romidepsin, Azacitidine, nab-Paclitaxel - Pancreas Cancer, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | GWT-TUD GmbH | 75 | 2020-05-25 | 2025-09-30 |
| Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Copanlisib, Romidepsin - Lymphoma, T-Cell | Phase 1 | Withdrawn | Columbia University | 2020-02-01 | 2020-08-13 | |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Tenalisib, Romidepsin - T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 33 | 2019-03-12 | 2022-10-28 |
| ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma Istodax - Lymphoma, T-Cell, Peripheral | Completed | Celgene | 150 | 2019-02-04 | 2023-12-06 | |
| Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Oral azacitidine, Romidepsin, Bendamustine - Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 86 | 2018-11-09 | 2026-04-23 |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Azacitidine, Romidepsin, Gemcitabine - Lymphoma, T-Cell | Phase 3 | Completed | Celgene | 93 | 2018-11-06 | 2026-06-12 |
| Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) Romidepsin, Ixazomib - Lymphoma, T-Cell, Peripheral | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 11 | 2018-09-26 | 2026-05-06 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Romidepsin, Pralatrexate - Lymphoma, T-Cell, Peripheral | Phase 3 | Withdrawn | Jennifer Amengual | 2018-09-01 | 2018-12-19 | |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Laboratory Biomarker Analysis, Romidepsin, Venetoclax - Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 12 | 2018-08-21 | 2023-10-19 |
| Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Durvalumab, Pralatrexate, Romidepsin - Lymphoma, T-Cell | Phase 1 / Phase 2 | Recruiting | University of Virginia | 148 | 2018-05-30 | 2022-03-31 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 23 | 2017-12-08 | 2025-09-19 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Romidepsin, Brentuximab vedotin - Cutaneous T-cell Lymphoma (CTCL) | Phase 1 | Completed | Fox Chase Cancer Center | 16 | 2017-02-22 | 2025-04-04 |
| Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART Romidepsin, 3BNC117, Antiretrovirals - Hiv | Phase 2 | Completed | Aarhus University Hospital | 60 | 2017-01-20 | 2025-04-18 |
Showing 20 of 97. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (20) · Lymphoma, T-Cell, Cutaneous (19) · Lymphoma, T-Cell (17) · Lymphoma (16) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, Large-Cell, Anaplastic (8) · Mycosis Fungoides (8) · Hodgkin Disease (7) · Lymphoma, Non-Hodgkin (7) · Multiple Myeloma (7) · Immunoblastic Lymphadenopathy (6) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (6) · Breast Neoplasms (5)
National Cancer Institute (NCI) (25) · Celgene (13) · Memorial Sloan Kettering Cancer Center (5) · Northwestern University (3) · The Lymphoma Academic Research Organisation (3) · Columbia University (2) · Fondazione Italiana Linfomi - ETS (2) · Jennifer Amengual (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Ohio State University Comprehensive Cancer Center (2) · SWOG Cancer Research Network (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Virginia (2) · Aarhus University Hospital (1)
United States (73) · United Kingdom (10) · France (6) · Germany (6) · Denmark (5) · Australia (4) · Italy (4) · Spain (4) · Belgium (3) · Canada (3) · Japan (3) · Poland (3) · Austria (2) · Czechia (2) · Portugal (2)
Ken Takeshita, MD (3) · Steven Horwitz, MD (3) · Nilofer Azad, MD (2) · William McCulloch, MB, FRCP (2) · Ai Wei, M.D. (1) · Amy Kimball, MD, PhD (1) · Anthony J Reiman (1) · Ashraf Badros (1) · Barbara Pro, MD (1) · Beata Holkova, MD (1) · Brigitte Miller (1) · Catherine Diefenbach, MD (1)
PMID 38796193, PMID 11675364, PMID 11895901, PMID 15466934, PMID 16859580, PMID 18245545, PMID 18941712, PMID 19826128, PMID 20697094, PMID 21355097, PMID 21377994, PMID 21911830, PMID 22271479, PMID 22536933, PMID 22748449, PMID 24456586, PMID 25279222, PMID 25605745, PMID 25891346, PMID 26379282, PMID 26687958, PMID 26965915, PMID 27071522, PMID 27658863, PMID 28103725, PMID 28264616, PMID 28664499, PMID 29141948, PMID 29622656, PMID 30301414, PMID 30707661, PMID 31012962, PMID 31471376, PMID 32632956, PMID 32838558, PMID 33171487, PMID 34398236, PMID 34750296, PMID 34843406, PMID 35544074, PMID 36253609, PMID 37327113, PMID 37439343, PMID 38364196, PMID 38517235, PMID 38886623, PMID 39725584, PMID 39863139, PMID 40179392, PMID 40932107
P30CA016672 (3), N01CM62204 (2), U10CA081851 (2), 2015 (1), N01CM17003 (1), N01CM17102 (1), N01CM62201 (1), N01CM62202 (1), N01CM62206 (1), P30CA012197 (1), P30CA013330 (1), P30CA014236 (1), P30CA014599 (1), P30CA015083 (1), P30CA016059 (1)